Allergan, the pharmaceutical company which brought the world Botox, has announced the launch of its new FDA approved prescription medication for lengthening eyelashes.
Latisse contains the same basic medication as Allergan's glaucoma eyedrops, Lumigan. Lumigan is a prostaglandin analog, which helps reduce the pressure in the eyes of glaucoma patients. Apparently a sharp eyed researcher discovered that a frequent side effect of Lumigan usage is longer, thicker eyelashes. (Other frequent side effects include discoloration of the iris and eye irritation.)
I saw a commercial for Latisse on television last night, which touted it as the Next Great Thing in beauty breakthroughs. Curious, I looked up some of the details online. I was flabbergasted when I found the price tag - about $120 a month, or $4 per day. And you have the double whammy: since it's a prescription medication, you have to see a doctor to get a prescription. But since it's a cosmetic prescription, your health insurance won't cover it. So I guess you can probably add in the cost of the initial doctor's visit to that tally.
However, Allergan could be right when they say that Latisse is going to be the next Botox. Botox has been a phenomenal earner for Allergan, and is fairly well accepted among women. And Latisse has that whole "not a deadly toxin" thing going for it.
Allergan admits that it does not really know how Latisse works, although "the company speculates that the drug may increase the length and amount of hair that sprouts during the growth cycle." Everyone wants to know if Latisse will work on hair elsewhere, such as the eyebrows and scalp, but Allergan is playing coy.
